electroCore rises on higher Q1 revenue forecast

electroCore,.

17/04/2023 17:09

** Shares of medical device maker electroCore Inc  ECOR.O 
up 9% at $6.88
    ** Co sees Q1 rev of $2.8 mln, up 46% from Q1 2022 rev of
about $1.9 mln
    ** Says 124 Department of Veterans Affairs and Department of
Defense military treatment facilities purchased co's gammaCore
products through March 31, 2023, as compared to 117 through
December 31, 2022
    ** Co reiterated FY2023 rev guidance of $14.0-$15.0 mln
    ** For FY2023, co sees legacy headache channels to grow by
more than 50% to at least $12 mln & rev from new products in the
Truvaga and TAC-STIM brands to be more than $2 mln
    ** ECOR up about 77.6% YTD

 (Reporting by Vaibhav  Sadhamta)
 ((Vaibhav.Sadhamta@thomsonreuters.com;))